[HTML][HTML] Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or EGFR-TKIs: a pooled analysis
JT Ma, J Sun, L Sun, SL Zhang, LT Huang, CB Han - Medicine, 2018 - journals.lww.com
Background: Apatinib is a tyrosine kinase inhibitor (TKI) that selectively inhibits the vascular
endothelial growth factor receptor-2. A weighted pooled analysis was performed to evaluate
the clinical outcome, efficacy, and toxicity of apatinib in patients with advanced nonsmall cell
lung cancer (NSCLC) that failed prior treatment with chemotherapy or epidermal growth
factor receptor-TKIs (EGFR-TKIs). Methods: The literature published in PubMed, Embase,
and Cochrane Library databases was searched (from inception to November 30, 2017) for …
endothelial growth factor receptor-2. A weighted pooled analysis was performed to evaluate
the clinical outcome, efficacy, and toxicity of apatinib in patients with advanced nonsmall cell
lung cancer (NSCLC) that failed prior treatment with chemotherapy or epidermal growth
factor receptor-TKIs (EGFR-TKIs). Methods: The literature published in PubMed, Embase,
and Cochrane Library databases was searched (from inception to November 30, 2017) for …
以上显示的是最相近的搜索结果。 查看全部搜索结果